Recombinant interleukin-2 and the quest for FDA approval.
Tami
J A
JA
D002292:Carcinoma, Renal Cell / Q000628:therapy*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D008545:Melanoma / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins